Inherited metabolic disorders can arise when a pathogenic genetic variant reduces the activity of an enzyme needed for a particular biochemical reaction. The resulting problem is not always a simple protein shortage. A substrate may accumulate, a necessary product may become scarce, or toxic metabolic intermediates may injure specific tissues. Several of these conditions can now be treated with recombinant enzymes, but the effectiveness of treatment depends on the disease, affected organs, and the ability of the administered enzyme to reach its target.

Enzyme replacement therapy (ERT) is a key example of how discoveries in genetics, cell biology, and biotechnology have led to targeted medicines. It is not, however, a universal solution for inherited metabolic disease. The experiences of Gaucher, Fabry, Pompe, and Tay-Sachs diseases illustrate both their clinical value and their limitations.

How inherited enzyme deficiencies cause disease

Genes encode proteins, including enzymes that catalyse specific biochemical reactions. Pathogenic variants may impair enzyme synthesis, folding, stability, transport or catalytic function. The residual activity can differ substantially between patients; it is therefore inaccurate to assume that an inherited enzyme disorder always involves total absence of the enzyme.

Many disorders treated by ERT are lysosomal storage diseases. Lysosomes contain enzymes that help break down macromolecules. When one pathway is disrupted, incompletely degraded material can accumulate inside cells. The identity of the stored substrate and the organs affected differ between diseases. Diagnosis generally combines clinical findings with enzyme activity assays and molecular genetic testing.

What is enzyme replacement therapy?

ERT supplies an active enzyme made outside the patient, often using recombinant expression systems, to compensate for reduced endogenous enzyme activity. Most lysosomal ERT medicines are delivered by intravenous infusion. Appropriate carbohydrate groups on the enzyme surface help cells take up the protein through receptor-mediated pathways and direct it to lysosomes. Some treatments use different delivery routes because their targets are outside lysosomes or because standard intravenous delivery would not reach the intended site.

Replacing an enzyme does not repair the pathogenic DNA variant. Treatment may need to continue long term, and it may be less effective in tissues with limited access to circulating proteins. Infusion reactions, anti-drug antibodies, disease stage and cost can also influence the practical benefit. In particular, the blood–brain barrier restricts how much of most intravenously administered enzyme reaches the central nervous system.

Gaucher disease: replacing glucocerebrosidase

Gaucher disease is caused by pathogenic variants in the GBA1 gene that reduce activity of lysosomal acid β-glucosidase, also called glucocerebrosidase. The material that accumulates is glucosylceramide (glucocerebroside), not the enzyme itself. Lipid-laden macrophages contribute to enlargement of the spleen and liver, blood-cell abnormalities and skeletal complications. The clinical spectrum includes neuronopathic forms as well as the more common non-neuronopathic type 1 disease.

Recombinant enzymes such as imiglucerase, velaglucerase alfa and taliglucerase alfa are established treatments for appropriate patients. They can improve many systemic manifestations, including organ enlargement and haematological abnormalities, but standard intravenously delivered ERT has limited effect on central nervous system disease. Substrate reduction therapies are another treatment category for selected patients; these reduce production of the material that cannot be cleared efficiently.

Fabry disease: replacing α-galactosidase A

Fabry disease is an X-linked condition caused by pathogenic GLA variants resulting in deficient lysosomal α-galactosidase A. Its major accumulating substrates include globotriaosylceramide (Gb3) and related metabolites. It can affect the kidneys, heart and nervous system, with substantial variation in severity among affected people. Females can also experience significant disease; they should not be regarded as unaffected carriers by default.

Enzyme-based treatments include agalsidase alfa, agalsidase beta and pegunigalsidase alfa, with availability and regulatory authorizations differing by region. These medicines aim to slow organ injury and reduce substrate accumulation, but established scarring and advanced damage may not be reversed. For some GLA variants, the oral pharmacological chaperone migalastat is another option. Migalastat is not an infused replacement enzyme; it helps stabilize certain mutant forms of the patient’s own enzyme, and eligibility depends on the specific variant.

Pompe disease: delivering acid α-glucosidase

Pompe disease, also known as glycogen storage disease type II, results from pathogenic variants in GAA and deficient lysosomal acid α-glucosidase. Glycogen accumulates particularly in cardiac and skeletal muscle. Infantile-onset disease can cause serious cardiomyopathy and weakness, whereas later-onset disease often features progressive skeletal and respiratory muscle involvement.

Alglucosidase alfa was the first widely used recombinant enzyme replacement for Pompe disease. Other approved options in specified patient groups include avalglucosidase alfa and cipaglucosidase alfa administered with miglustat. These treatments aim to improve glycogen clearance and preserve motor or respiratory function, but outcomes vary. Immune responses to the infused protein are particularly important in some infants, and treatment often requires specialized monitoring and supportive care.

ADA-SCID: enzyme replacement for an inherited immune disorder

Adenosine deaminase–deficient severe combined immunodeficiency (ADA-SCID) is an inherited disorder of purine metabolism. Deficiency of ADA allows toxic purine metabolites to accumulate and disrupt the development and survival of immune cells. This example differs from the lysosomal storage disorders: the essential problem is metabolic toxicity affecting immune function.

Elapegademase, a polyethylene glycol–modified recombinant ADA preparation, is an approved enzyme replacement option in the United States. It can reduce toxic metabolites and support immune recovery, sometimes serving as a bridge while a patient is assessed for haematopoietic stem-cell transplantation or gene therapy. The choice and timing of treatment are determined by specialist immunology teams; ERT does not automatically provide permanent correction of the underlying disorder.

Tay-Sachs disease: why enzyme replacement remains difficult

Tay–Sachs disease is caused by pathogenic variants in HEXA that markedly reduce activity of β-hexosaminidase A. GM2 ganglioside accumulates especially in neurons, causing progressive neurological injury. The missing enzyme is not “hexose deaminase,” as stated in the original 2018 lecture note.

Unlike Gaucher and Fabry diseases, Tay–Sachs disease does not currently have an approved disease-modifying ERT. One major obstacle is delivering sufficient active enzyme into the brain across the blood–brain barrier. Researchers are investigating enzyme-delivery strategies, gene therapy and other approaches, but experimental work must not be described as established clinical treatment. Current management remains predominantly supportive and multidisciplinary.

Comparing inherited diseases and enzyme-based treatments

What about diet modification and other metabolic therapies?

Not every inherited enzyme disorder is best treated by infusing a missing enzyme. Phenylketonuria, for example, is often managed through dietary phenylalanine restriction and other disease-specific treatments. More broadly, substrate reduction therapies lower synthesis of accumulating molecules, while pharmacological chaperones stabilize selected enzyme variants. Gene and cell therapies seek to address a different level of the underlying problem. The choice depends on the biochemical defect, available evidence, regulatory authorization, and individual patient circumstances.

Other therapeutic enzymes are not necessarily treatments for genetic disease

The original lecture notes also mentioned pancreatic enzymes, streptokinase, urokinase, collagenase and papain. They belong to the broader subject of therapeutic enzymes, but they should not be mixed with ERT for inherited metabolic disorders. Pancreatic enzyme replacement supplies digestive enzymes to people with exocrine pancreatic insufficiency, which may arise from cystic fibrosis or acquired pancreatic disease. Streptokinase and urokinase activate fibrinolysis and have been used in selected thrombotic settings. Collagenase preparations are used for selected wound-debridement indications. These applications address quite different clinical processes; their suitability and licensing vary by country.

The earlier notes also attributed Fabry disease to glucose-6-phosphate dehydrogenase deficiency. That is incorrect: G6PD deficiency is a separate inherited red-cell enzyme disorder associated with vulnerability to oxidative haemolysis. It is not the cause of Fabry disease and is not treated by giving patients recombinant α-galactosidase.

Limitations and future directions

ERT illustrates precision treatment, but delivery remains a major challenge. Tissue uptake may be uneven; irreversible organ injury can limit recovery; immune reactions may complicate repeated infusions; and specialist treatment can be expensive. Current research includes improved enzyme targeting, longer-lasting formulations, approaches to central nervous system delivery, gene and messenger-RNA therapies, and combinations with other metabolic treatments.

Recent Pompe and Fabry studies also show why treatment effectiveness cannot be reduced to one laboratory biomarker. Researchers assess organ function, symptoms, quality of life, safety and disease progression over time. Small studies, heterogeneous patient groups and short follow-up can make comparisons uncertain. A newer enzyme formulation should not automatically be called superior without appropriate clinical evidence.

Conclusion

The therapeutic use of enzymes for inherited disease is one of the clearest links between enzymology and modern medicine. Recombinant enzymes have transformed care for several conditions, including Gaucher, Fabry, and Pompe diseases, while ADA replacement supports patients with a serious inherited immunodeficiency. Tay-Sachs disease demonstrates an equally important limitation: providing the right enzyme is not enough if it cannot reach the affected tissue. For students, the central principle is to connect the defective gene, the lost enzyme function, the accumulated substrate, and the actual evidence for each treatment.

References and further reading

1. GeneReviews® — Gaucher Disease (updated clinical review) https://www.ncbi.nlm.nih.gov/books/NBK1269/

2. Mehta, A., & Hughes, D. A. (2024). Fabry Disease. GeneReviews®. https://www.ncbi.nlm.nih.gov/books/NBK1292/

3. Sperry, E., Leslie, N., Berry, L., & Pena, L. (2025). Pompe Disease. GeneReviews®. https://www.ncbi.nlm.nih.gov/books/NBK1261/

4. GeneReviews® — HEXA Disorders (Tay–Sachs disease). https://www.ncbi.nlm.nih.gov/sites/books/NBK1218/

5. GeneReviews® — Adenosine Deaminase Deficiency. https://www.ncbi.nlm.nih.gov/books/NBK1483/

6. Germain, D. P., & Linhart, A. (2024). Pegunigalsidase alfa: A novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. Frontiers in Genetics, 15, 1395287. https://doi.org/10.3389/fgene.2024.1395287

7. Therapeutic Strategies for Tay-Sachs Disease. (2022). Frontiers in Pharmacology, 13, 906647. https://doi.org/10.3389/fphar.2022.906647

8. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Exocrine Pancreatic Insufficiency. https://www.niddk.nih.gov/health-information/digestive-diseases/exocrine-pancreatic-insufficiency/treatment

9. U.S. Food and Drug Administration. Revcovi approval and clinical superiority information. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings